Loading...
  • clonal
  • Polycythaemia vera (PV) is a clonal haematological malignancy characterised by pronounced symptoms, including fatigue, pruritus and symptomatic splenomegaly, along with an increased risk of thrombosis and the potential for evolution to myelofibrosis and secondary acute myeloid leukemia [ 1 ] . (patient.info)
  • Life Expectancy
  • Life expectancy of the patients who still displayed P. vera was more favorable than those cases with transformation into CMGM, disregarding any therapy. (springer.com)
  • There is no cure, but recent research suggests that individuals who have primary polycythemia may significantly increase their overall life expectancy by seeking treatment right away. (uvahealth.com)
  • JAK2V617F
  • The JAK2V617F mutation leads to constitutive phosphorylation, thus constitutive activity and STAT recruitment, which provides the proliferative advantage seen in polycythemia vera. (medscape.com)
  • Polycythemia vera is caused by a mutation in the JAK2V617F gene, notes Healthline. (reference.com)
  • In the present study, we describe the effects of vorinostat, a small-molecule inhibitor of histone deacetylase, against cells expressing JAK2V617F and in an animal model of polycythemia vera (PV). (nih.gov)
  • erythremia
  • In addition to a complete medical history and physical examination, diagnostic procedures for polycythemia may include blood tests to observe the increased number of red blood cells in the body, and distinguish it from other conditions which could cause the red blood cell count to increase (such as certain cardiac and respiratory diseases, erythremia, and certain tumors). (nyhq.org)
  • acute leukemia
  • A blast crisis or so called acute leukemia in P. vera was seen only in one patient who was treated by an overdose of radioactive phosphorus and later evolved into osteomyelosclerosis with blastic transformation. (springer.com)
  • 2017
  • Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape. (mynewsdesk.com)
  • Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. (mynewsdesk.com)
  • nonspecific
  • Many individuals with polycythemia vera slowly development a variety of general, nonspecific symptoms that are common to many disorders such as headaches, fatigue, weakness, dizziness, excessive sweating especially at night, and itchy skin that, in severe cases, may be worse after taking a shower or a warm bath. (rarediseases.org)